Press Releases from Hyperkalemia Therapeutics - Pharma Proff (1 total)
Hyperkalemia Therapeutics - Pipeline Analysis 2018 | Ardelyx, Inc., Relypsa
Hyperkalemia is referred to as increased levels of potassium in blood which results in cardiac arrest and death. Potassium levels above 5.1 mEq/l are considered…
Go To Page:
